Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives

ABSTRACT Introduction: Hematopoietic cell transplantation is a potentially lifesaving procedure for patients with hematological malignancies who are refractory to conventional chemotherapy and/or irradiation treatment. Umbilical cord blood (CB) transplantation, as a hematopoietic stem and progenitor cell (HSPC) source, has several advantages over bone marrow transplantation with respect to matching and prompt availability for transplantation. Additionally, CB has some inherent features, such as rapid expansion of T cells, lower prevalence of graft-versus-host disease and higher graft versus tumor efficacy that make this HSPC cell source more favorable over other HSPC sources. Areas covered: This review summarizes the current CB and CB derived T cell applications aiming to better disease control for hematological malignancies and discusses future directions to more effective therapies. Expert commentary: CB transplantation could be used as a platform to extract cord blood derived T cells for ex vivo expansion and/or gene modification to improve cellular immunotherapies. In addition, combining cord blood gene-engineered T cell products with vaccination strategies, such as cord blood derived dendritic cell based vaccines, may provide synergistic immunotherapies with enhanced anti-tumor effects.

[1]  R. Blasczyk,et al.  Cord blood–derived T cells allow the generation of a more naïve tumor‐reactive cytotoxic T‐cell phenotype , 2018, Transfusion.

[2]  A. Wensing,et al.  Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation , 2017, The Journal of allergy and clinical immunology.

[3]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[4]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[5]  H. Abken,et al.  Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities , 2017, Oncoimmunology.

[6]  C. van Kesteren,et al.  Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. , 2016, Blood.

[7]  S. Nierkens,et al.  Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. , 2016, Blood.

[8]  H. Abken,et al.  The growing world of CAR T cell trials: a systematic review , 2016, Cancer Immunology, Immunotherapy.

[9]  F. Appelbaum,et al.  Cord-Blood Transplantation in Patients with Minimal Residual Disease. , 2016, The New England journal of medicine.

[10]  K. Rezvani,et al.  PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. , 2016, Cytotherapy.

[11]  K. Peggs,et al.  Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. , 2016, Cytotherapy.

[12]  J. Boelens.  The power of cord blood cells. , 2016, Blood.

[13]  Renier J. Brentjens,et al.  Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.

[14]  J. Madrigal,et al.  Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells. , 2016, Cytotherapy.

[15]  Chun Jimmie Ye,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells , 2016, Scientific Reports.

[16]  S. Kenney,et al.  PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model , 2016, PLoS pathogens.

[17]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[18]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[19]  S. Quezada,et al.  TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. , 2016, Cancer research.

[20]  S. Albelda,et al.  Chimeric antigen receptor T-cell therapy for solid tumors , 2016, Molecular therapy oncolytics.

[21]  D. Bartlett,et al.  Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer , 2016, Oncotarget.

[22]  Coco de Koning,et al.  Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[24]  S. Quezada,et al.  Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. , 2015, Blood.

[25]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[26]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[27]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[28]  L. Boon,et al.  Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation , 2015, Oncoimmunology.

[29]  Hao Liu,et al.  Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Egberts,et al.  Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. , 2015, The Lancet. Haematology.

[31]  C. Mackall,et al.  Going back to class I: MHC and immunotherapies for childhood cancer , 2015, Pediatric blood & cancer.

[32]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[33]  R. Orentas,et al.  Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.

[34]  C. Heirman,et al.  mRNA-based dendritic cell vaccines , 2015, Expert review of vaccines.

[35]  Elise Langenkamp,et al.  VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Richard L. Frock,et al.  Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.

[37]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[38]  B. Palmer,et al.  Naïve T cells, unconventional NK and NKT cells, and highly responsive monocyte-derived macrophages characterize human cord blood. , 2014, Immunobiology.

[39]  S. Giralt,et al.  IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia , 2014, Leukemia.

[40]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[41]  Krishnendu Roy,et al.  Generation of Functional, Antigen‐Specific CD8+ Human T Cells from Cord Blood Stem Cells Using Exogenous Notch and Tetramer‐TCR Signaling , 2014, Stem cells.

[42]  P. Darcy,et al.  Blockade of PD-1 immunosuppression boosts CAR T-cell therapy , 2013, Oncoimmunology.

[43]  K. Ballen,et al.  Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.

[44]  P. Darcy,et al.  Gene-engineered T cells for cancer therapy , 2013, Nature Reviews Cancer.

[45]  U. Gerdemann,et al.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant , 2013, Leukemia.

[46]  P. Veys,et al.  Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients , 2013, Bone Marrow Transplantation.

[47]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[48]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[49]  J. Gribben,et al.  Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC , 2012, PloS one.

[50]  F. Mami-Chouaib,et al.  Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. , 2012, Cancer research.

[51]  Delong Liu,et al.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy , 2012, Experimental Hematology & Oncology.

[52]  F. Appelbaum.  Pursuing the goal of a donor for everyone in need. , 2012, The New England journal of medicine.

[53]  I. Melero,et al.  Changing the tumor microenvironment: new strategies for immunotherapy. , 2012, Cancer research.

[54]  M. Ciofani,et al.  Comparative and Functional Evaluation of In Vitro Generated to Ex Vivo CD8 T Cells , 2012, The Journal of Immunology.

[55]  Luigi Naldini,et al.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. , 2012, Blood.

[56]  H. Levitsky,et al.  Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape , 2012, Clinical & developmental immunology.

[57]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[58]  P. Veys,et al.  Omission of in vivo T‐cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant , 2012, British journal of haematology.

[59]  Hao Liu,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[60]  M. Duval,et al.  CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. , 2011, Blood.

[61]  Yong-soo Lee,et al.  T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor , 2011, BMC Cancer.

[62]  S. Witting,et al.  Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. , 2011, Blood.

[63]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[64]  G. Sempowski,et al.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. , 2010, Cancer research.

[65]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[66]  S. Cingarlini,et al.  IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. , 2010, Vaccine.

[67]  P. Hanley,et al.  Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. , 2010, Blood.

[68]  Rafael Araos B.  Linfocitos T específicos contra CMV, ADV y VEB a partir de linfocitos T naive provenientes de sangre de cordón umbilical , 2010 .

[69]  O. Ringdén,et al.  Clinical Expansion of Cord Blood-derived T Cells for Use as Donor Lymphocyte Infusion After Cord Blood Transplantation , 2010, Journal of immunotherapy.

[70]  P. Hanley,et al.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. , 2009, Blood.

[71]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[72]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[73]  T. Schumacher,et al.  Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors1 , 2007, The Journal of Immunology.

[74]  J. Klein,et al.  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study , 2007, The Lancet.

[75]  S. Rosenberg,et al.  Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. , 2007, Cancer research.

[76]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[77]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[78]  David D. Smith,et al.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. , 2006, Blood.

[79]  M. Burdick,et al.  CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.

[80]  N. Schmitz,et al.  Hematopoietic stem cell transplantation for hematological malignancies in Europe , 2003, Leukemia.

[81]  A. Zander,et al.  Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. , 2001, Blood.

[82]  S. Riddell,et al.  Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1 , 2001, The Journal of Immunology.

[83]  J. Dick,et al.  Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. , 1997, Blood.

[84]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[85]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[86]  H. Broxmeyer,et al.  Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Alexander J. Nelson,et al.  Cell intrinsic characteristics of human cord blood naïve CD4T cells. , 2018, Immunology letters.

[88]  C. Bonini,et al.  Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. , 2016, Biochimica et biophysica acta.

[89]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[90]  G. Wagemaker,et al.  Lentiviral gene transduction of mouse and human hematopoietic stem cells. , 2014, Methods in molecular biology.

[91]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.